← Eichor
Condition: Ovarian Metastasis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ovarian Metastasis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07451483Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT02830724Establishment of a Tumor Bank for Blood Samples
Phase N/A · 6 location(s) · Medical University of Vienna · NCT01763125Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Mainte
NA · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05607329First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Se
Phase 1 · 3 location(s) · Molecure S.A. · NCT05759923Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1 · 3 location(s) · ImmVirx Pty Ltd · NCT05427487A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
Phase 1 · 2 location(s) · Shanghai Best-Link Bioscience, LLC · NCT06738966Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT00722228A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Phase 1 · 2 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT05746897A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05803018A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Phase 2 · 1 location(s) · Nabil Adra · NCT04804007Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 · 39 location(s) · SystImmune Inc. · NCT05983432Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Phase 2 · 2 location(s) · Tel-Aviv Sourasky Medical Center · NCT06839144A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Parti
Phase 2 · 54 location(s) · Bayer · NCT06760819DBC-664 in Adult Patients With Solid Tumors
Phase 1 · 3 location(s) · Duboce Biopharmaceuticals, Inc. · NCT07705035Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 18 location(s) · MOMA Therapeutics · NCT06545942Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction
Phase 1 · 2 location(s) · University of Utah · NCT04315233SL-28 for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Second Life Therapeutics · NCT07341737Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Can
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05123807Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 · 21 location(s) · Clasp Therapeutics, Inc. · NCT06778863A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai
Phase 2 · 1 location(s) · Korea University Guro Hospital · NCT05704621Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Phase 1 · 9 location(s) · Avacta Life Sciences Ltd · NCT04969835A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05251883
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.